ESGO 2026

Endometrial cancer classification is evolving, and we're bringing innovative solutions to the table!

Our MODAPLEX Endometrial Cancer Panel streamlines molecular profiling by combining POLE/POLD1 mutations, microsatellite instability (MSI), and copy number variation analysis into one seamless workflow, delivering comprehensive results in just 4 hours. With minimal DNA input, it maximizes FFPE tissue conservation while enabling fast, informed profiling based on ESGO-recommended TCGA classification.

Looking only for a solution for POLE testing?

For a comprehensive POLE/POLD1 mutation analysis, we recommend our MODAPLEX POLE/POLD1 Mutation Analysis Kit, which covers 19 mutations in the POLE and POLD1 genes, accounting for up to 96% of cases*.

For a qPCR-based approach, we recommend our qPCR POLE Mutation Analysis Kit, which offers a focused analysis of 6 high-frequency POLE mutations, covering approximately 86% of cases*.

Arrange a meeting with Stefan Albrecht-Lienau at ESGO 2026 and explore how BIOTYPE is shaping the future of molecular cancer research!

*Case data based on entries in GENIE Cohort v.15.1 for endometrial cancer (Cerami, E. et al. Cancer Discov; 10.1158/2159-8290.CD-12-0095, 2012; Gao, J. et al. Sci Signal; 10.1126/scisignal.2004088, 2013)